Literature DB >> 15517019

Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells.

Julian Downward1.   

Abstract

Over the past decade, 'RNA interference' has emerged as a natural mechanism of silencing of gene expression. This ancient cellular antiviral response can be manipulated to provide an effective research tool to knock down the level of expression of selected target genes, providing a very powerful new method for the analysis of cell signalling pathways. Systematic silencing of genes on a genome-wide scale using large rationally designed libraries targeting many thousands of genes provides a novel functional genomics approach to the investigation of many aspects of mammalian cell behaviour, including oncogenic transformation. Here, the different approaches taken to use RNA interference libraries to study the cancer phenotype will be considered, including both selective and high throughput screens and the use of both vector-based and synthetic oligonucleotide-based methods for inducing RNA interference. The advantages and drawbacks of the competing methodologies will be discussed. RNA interference library technology holds great promise for enabling somatic cell genetics in tissue culture systems. Whether it can provide significant new insights into cancer will be its greatest challenge.

Entities:  

Mesh:

Year:  2004        PMID: 15517019     DOI: 10.1038/sj.onc.1208073

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  WT1: a weak spot in KRAS-induced transformation.

Authors:  Silvia Licciulli; Joseph L Kissil
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

2.  A retroviral vector for siRNA expression in mammalian cells.

Authors:  Gro Leite Størvold; Elisabet Gjernes; Hanne Arenberg Askautrud; Anne-Lise Børresen-Dale; Charles M Perou; Eirik Frengen
Journal:  Mol Biotechnol       Date:  2007-03       Impact factor: 2.695

3.  Ligand-induced MET signaling as targetable codependence in acute myeloid leukemia.

Authors:  Stefan Fröhling
Journal:  Haematologica       Date:  2012-08       Impact factor: 9.941

Review 4.  Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.

Authors:  Arshawn Sami; Michael Karsy
Journal:  Tumour Biol       Date:  2013-04-30

5.  Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells.

Authors:  Y Wang; V N Ngo; M Marani; Y Yang; G Wright; L M Staudt; J Downward
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

6.  Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Authors:  Charles Swanton; James M Larkin; Marco Gerlinger; Aron C Eklund; Michael Howell; Gordon Stamp; Julian Downward; Martin Gore; P Andrew Futreal; Bernard Escudier; Fabrice Andre; Laurence Albiges; Benoit Beuselinck; Stephane Oudard; Jens Hoffmann; Balázs Gyorffy; Chris J Torrance; Karen A Boehme; Hansjuergen Volkmer; Luisella Toschi; Barbara Nicke; Marlene Beck; Zoltan Szallasi
Journal:  Genome Med       Date:  2010-08-11       Impact factor: 11.117

7.  Single cell cytometry of protein function in RNAi treated cells and in native populations.

Authors:  Peter LaPan; Jing Zhang; Jing Pan; Andrew Hill; Steven A Haney
Journal:  BMC Cell Biol       Date:  2008-08-01       Impact factor: 4.241

8.  Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components.

Authors:  Amarsanaa Jazag; Fumihiko Kanai; Hideaki Ijichi; Keisuke Tateishi; Tsuneo Ikenoue; Yasuo Tanaka; Miki Ohta; Jun Imamura; Bayasi Guleng; Yoshinari Asaoka; Takao Kawabe; Makoto Miyagishi; Kazunari Taira; Masao Omata
Journal:  Nucleic Acids Res       Date:  2005-08-19       Impact factor: 16.971

9.  Broad network-based predictability of Saccharomyces cerevisiae gene loss-of-function phenotypes.

Authors:  Kriston L McGary; Insuk Lee; Edward M Marcotte
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

Review 10.  Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.

Authors:  Charles Swanton; Zoltan Szallasi; James D Brenton; Julian Downward
Journal:  Breast Cancer Res       Date:  2008-10-31       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.